Evergreen Talk Series: Combination of Linagliptin and Dapagliflozin in T2DM with multiple episodes of hypoglycemia MDTV Bureau21 Feb 2024 9:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
Dapagliflozin leads to modest reduction in systolic BP in patients with CKD and albuminuria: Study Medha Baranwal21 Feb 2024 3:00 AM ISTUSA: Treatment with dapagliflozin in patients with chronic kidney disease (CKD) and albuminuria is associated with modest but clinically meaningful...
Akums Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug Dr. Divya Colin13 Feb 2024 6:00 PM ISTNew Delhi: The drug major Akum Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Top 10 Messages from Evergreen Webinar on Clinical Applicability of Linagliptin Dapagliflozin in Type 2 Diabetes, Addressed by Dr V Mohan Dr Jeegar Dattani12 Feb 2024 12:15 PM ISTDr. V. Mohan, M.D., FRCP (London, Edinburgh, Glasgow & Ireland), Ph.D., D.Sc. D.Sc (Hon. Causa), FNASc, FASc, FNA, FACE, FACP, FTWAS, MACP, FRSE....
Dapagliflozin therapy helps reduce CV mortality in heart failure with improved ejection fraction: JAMA Medha Baranwal1 Feb 2024 11:00 AM ISTUSA: Adding a sodium-glucose transport protein 2 inhibitor therapy to other guideline-directed medical therapies may help lower cardiovascular...
Evergreen Talk Series: Use of SGLT2i and DPP4i combination in T2DM patients with a history of Genitourinary Tract Infections MD Brand Connect1 Feb 2024 10:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani,...
Evergreen Talk Series: Position paper published in JAPI indicated that Linagliptin is simplifying T2DM management in a Wide Range of Patients MDTV Bureau23 Jan 2024 11:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
No need to discontinue SGLT2 inhibitors in response to initial eGFR decline in heart failure patients Medha Baranwal6 Jan 2024 11:00 AM ISTUSA: SGLT2 inhibitors should not be discontinued in response to an initial decline in the estimated glomerular filtration rate (eGFR) among patients...
Lupin bags tentative USFDA nod for Dapagliflozin and Saxagliptin Tablets Ruchika Sharma5 Jan 2024 11:11 AM ISTDapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes...
Evergreen Talk Series: Clinical Considerations for Linagliptin and its combinations with Metformin, Dapagliflozin MD Brand Connect2 Jan 2024 11:00 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani,...
Lupin Launches Dapaturn GM Range for Improved Approach to Manage Type 2 Diabetes MD Brand Connect1 Jan 2024 11:45 AM ISTGlobal pharma major Lupin Limited announced the launch of Dapaturn GM Forte for the treatment of diabetic patients in India. Lupin's Dapaturn GMâ„¢...
Dapagliflozin with semaglutide combo may help induce pharmacological remission of type 2 diabetes Jacinthlyn Sylvia29 Dec 2023 1:45 AM ISTA recent observational study unveiled positive outcomes regarding the combination therapy of a sodium-glucose co-transporter-2 inhibitor,...
